Catalent Key Executives
This section highlights Catalent's key executives, including their titles and compensation details.
Find Contacts at Catalent
(Showing 0 of )
Catalent Earnings
This section highlights Catalent's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2024 | 2023-11-15 | $-0.13 | $-0.10 |
| Read Transcript | Q4 | 2023 | 2023-08-29 | $0.10 | $0.09 |
| Read Transcript | Q3 | 2023 | 2023-06-12 | $-0.13 | $-0.09 |
| Read Transcript | Q2 | 2023 | 2023-02-07 | $0.72 | $0.67 |
| Read Transcript | Q1 | 2023 | 2022-11-01 | $0.55 | $0.34 |
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
$63.48
Stock Price
$11.52B
Market Cap
1.60K
Employees
Somerset, NJ
Location
Financial Statements
Access annual & quarterly financial statements for Catalent, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | June 30, 2024 | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 |
|---|---|---|---|---|---|
| Revenue | $4.38B | $4.28B | $4.83B | $4.00B | $3.09B |
| Cost of Revenue | $3.43B | $3.22B | $3.19B | $2.65B | $2.11B |
| Gross Profit | $953.00M | $1.06B | $1.64B | $1.35B | $983.30M |
| Gross Profit Ratio | 21.80% | 24.80% | 33.97% | 33.80% | 31.78% |
| Research and Development Expenses | $- | $18.00M | $23.00M | $21.00M | $63.80M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $935.00M | $831.00M | $844.00M | $687.00M | $577.90M |
| Other Expenses | $767.00M | $6.00M | $41.00M | $19.00M | $-7.90M |
| Operating Expenses | $1.70B | $987.00M | $885.00M | $706.00M | $577.90M |
| Cost and Expenses | $5.13B | $4.20B | $4.07B | $3.35B | $2.69B |
| Interest Income | $- | $184.00M | $123.00M | $110.00M | $126.00M |
| Interest Expense | $254.00M | $184.00M | $123.00M | $110.00M | $126.10M |
| Depreciation and Amortization | $489.00M | $422.00M | $378.00M | $289.00M | $253.70M |
| EBITDA | $-284.00M | $266.00M | $1.08B | $1.11B | $640.20M |
| EBITDA Ratio | -6.48% | 1.85% | 15.06% | 16.08% | 12.85% |
| Operating Income | $-749.00M | $-137.00M | $349.00M | $354.00M | $143.80M |
| Operating Income Ratio | -17.10% | -3.20% | 7.23% | 8.85% | 4.65% |
| Total Other Income Expenses Net | $-278.00M | $-179.00M | $-151.00M | $-113.00M | $-133.60M |
| Income Before Tax | $-1.03B | $-315.00M | $605.00M | $715.00M | $260.40M |
| Income Before Tax Ratio | -23.44% | -7.37% | 12.53% | 17.88% | 8.42% |
| Income Tax Expense | $16.00M | $-83.00M | $86.00M | $130.00M | $39.70M |
| Net Income | $-1.04B | $-232.00M | $499.00M | $585.00M | $173.00M |
| Net Income Ratio | -23.81% | -5.43% | 10.34% | 14.63% | 5.59% |
| EPS | $-5.76 | $-1.28 | $2.74 | $3.15 | $1.15 |
| EPS Diluted | $-5.76 | $-1.28 | $2.71 | $3.11 | $1.14 |
| Weighted Average Shares Outstanding | 181.00M | 181.00M | 176.00M | 168.00M | 149.79M |
| Weighted Average Shares Outstanding Diluted | 181.00M | 181.00M | 178.00M | 170.00M | 152.32M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.02B | $1.30B | $1.07B | $1.02B | $982.00M | $1.07B | $1.04B | $1.15B | $1.02B | $1.31B | $1.27B | $1.22B | $1.02B | $1.19B | $1.05B | $910.80M | $845.70M | $947.60M | $760.60M | $721.40M |
| Cost of Revenue | $842.00M | $917.00M | $845.00M | $853.00M | $801.00M | $833.00M | $857.00M | $762.00M | $764.00M | $825.00M | $850.00M | $812.00M | $701.00M | $749.00M | $687.70M | $612.60M | $596.80M | $613.00M | $521.80M | $489.20M |
| Gross Profit | $181.00M | $384.00M | $229.00M | $171.00M | $181.00M | $235.00M | $180.00M | $387.00M | $258.00M | $488.00M | $423.00M | $405.00M | $324.00M | $439.00M | $365.60M | $298.20M | $248.90M | $334.60M | $238.80M | $232.20M |
| Gross Profit Ratio | 17.70% | 29.50% | 21.30% | 16.70% | 18.40% | 22.00% | 17.40% | 33.70% | 25.20% | 37.20% | 33.20% | 33.30% | 31.60% | 37.00% | 34.70% | 32.70% | 29.40% | 35.31% | 31.40% | 32.19% |
| Research and Development Expenses | $- | $5.00M | $4.00M | $4.00M | $4.00M | $5.00M | $4.00M | $4.00M | $5.00M | $5.00M | $6.00M | $6.00M | $6.00M | $6.00M | $3.40M | $6.00M | $6.00M | $5.60M | $5.90M | $4.90M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $419.90M | $136.10M | $141.00M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-261.90M | $- | $- |
| Selling General and Administrative Expenses | $252.00M | $218.00M | $214.00M | $180.00M | $215.00M | $219.00M | $190.00M | $226.00M | $196.00M | $226.00M | $207.00M | $228.00M | $183.00M | $184.00M | $172.70M | $165.50M | $164.70M | $158.00M | $136.10M | $141.00M |
| Other Expenses | $- | $-1.00M | $-2.00M | $-3.00M | $-13.00M | $4.00M | $15.00M | $23.00M | $2.00M | $2.00M | $5.00M | $1.00M | $4.00M | $2.00M | $-500.00K | $8.10M | $10.60M | $29.30M | $-26.00M | $11.10M |
| Operating Expenses | $252.00M | $224.00M | $246.00M | $187.00M | $216.00M | $335.00M | $205.00M | $249.00M | $198.00M | $242.00M | $212.00M | $244.00M | $187.00M | $186.00M | $172.70M | $165.50M | $164.70M | $158.00M | $136.10M | $141.00M |
| Cost and Expenses | $1.09B | $1.14B | $1.09B | $1.04B | $1.02B | $1.17B | $1.06B | $1.01B | $962.00M | $1.07B | $1.06B | $1.06B | $888.00M | $935.00M | $860.40M | $778.10M | $761.50M | $771.00M | $657.90M | $630.20M |
| Interest Income | $- | $- | $- | $- | $- | $54.00M | $51.00M | $47.00M | $32.00M | $- | $- | $- | $26.00M | $- | $27.00M | $25.00M | $26.00M | $16.10M | $- | $- |
| Interest Expense | $60.00M | $65.00M | $65.00M | $66.00M | $58.00M | $54.00M | $51.00M | $47.00M | $32.00M | $32.00M | $33.00M | $32.00M | $- | $32.00M | $- | $- | $- | $20.50M | $34.40M | $34.90M |
| Depreciation and Amortization | $113.00M | $130.00M | $126.00M | $121.00M | $112.00M | $114.00M | $106.00M | $103.00M | $99.00M | $100.00M | $99.00M | $98.00M | $81.00M | $73.00M | $75.90M | $71.00M | $69.00M | $66.40M | $64.80M | $61.90M |
| EBITDA | $56.00M | $290.00M | $105.00M | $5.00M | $-627.00M | $18.00M | $-125.00M | $264.00M | $134.00M | $343.00M | $312.00M | $245.00M | $214.00M | $326.00M | $419.90M | $205.90M | $162.00M | $265.90M | $128.90M | $155.30M |
| EBITDA Ratio | 5.47% | 22.29% | 9.96% | 10.25% | -4.89% | -8.99% | -2.03% | 20.80% | 15.56% | 26.50% | 24.51% | 21.36% | 21.27% | 21.46% | 23.84% | 23.25% | 19.38% | 21.73% | 16.50% | 22.76% |
| Operating Income | $-71.00M | $160.00M | $-17.00M | $-16.00M | $-735.00M | $-100.00M | $-25.00M | $138.00M | $60.00M | $246.00M | $211.00M | $161.00M | $138.00M | $251.00M | $368.60M | $126.60M | $81.50M | $170.20M | $100.80M | $89.00M |
| Operating Income Ratio | -6.94% | 12.30% | -1.58% | -1.56% | -74.85% | -9.36% | -2.41% | 12.01% | 5.87% | 18.74% | 16.58% | 13.23% | 13.46% | 21.13% | 34.99% | 13.90% | 9.64% | 17.96% | 13.25% | 12.34% |
| Total Other Income Expenses Net | $-46.00M | $-122.00M | $-92.00M | $-100.00M | $-71.00M | $-149.00M | $-47.00M | $-24.00M | $-57.00M | $-35.00M | $-35.00M | $-46.00M | $-35.00M | $-30.30M | $-51.50M | $-23.00M | $-14.60M | $8.80M | $-71.10M | $-30.50M |
| Income Before Tax | $-117.00M | $38.00M | $-86.00M | $-182.00M | $-806.00M | $-150.00M | $-282.00M | $114.00M | $3.00M | $211.00M | $176.00M | $115.00M | $103.00M | $221.00M | $317.10M | $109.00M | $67.40M | $179.00M | $29.70M | $58.50M |
| Income Before Tax Ratio | -11.44% | 2.92% | -8.01% | -17.77% | -82.08% | -14.04% | -27.19% | 9.92% | 0.29% | 16.07% | 13.83% | 9.45% | 10.05% | 18.60% | 30.11% | 11.97% | 7.97% | 18.89% | 3.90% | 8.11% |
| Income Tax Expense | $12.00M | $15.00M | $15.00M | $24.00M | $-91.00M | $-64.00M | $-55.00M | $33.00M | $3.00M | $23.00M | $35.00M | $18.00M | $10.00M | $39.00M | $85.30M | $20.60M | $-15.00M | $24.80M | $8.80M | $13.00M |
| Net Income | $-129.00M | $23.00M | $-101.00M | $-206.00M | $-715.00M | $-86.00M | $-227.00M | $81.00M | $- | $187.00M | $141.00M | $93.00M | $84.00M | $168.90M | $217.00M | $77.00M | $69.00M | $134.30M | $20.90M | $34.30M |
| Net Income Ratio | -12.61% | 1.77% | -9.40% | -20.12% | -72.81% | -8.05% | -21.89% | 7.05% | 0.00% | 14.24% | 11.08% | 7.64% | 8.20% | 14.22% | 20.60% | 8.45% | 8.16% | 14.17% | 2.75% | 4.75% |
| EPS | $-0.71 | $0.13 | $-0.55 | $-1.13 | $-3.95 | $-0.48 | $-1.25 | $0.45 | $0.00 | $1.04 | $0.78 | $0.53 | $0.49 | $0.98 | $1.27 | $0.46 | $0.42 | $0.86 | $0.14 | $0.23 |
| EPS Diluted | $-0.71 | $0.13 | $-0.55 | $-1.13 | $-3.95 | $-0.48 | $-1.25 | $0.45 | $0.00 | $1.04 | $0.78 | $0.52 | $0.49 | $0.97 | $1.26 | $0.45 | $0.41 | $0.85 | $0.14 | $0.23 |
| Weighted Average Shares Outstanding | 182.00M | 181.00M | 182.00M | 182.00M | 181.00M | 181.00M | 181.00M | 181.00M | 180.00M | 180.00M | 180.00M | 175.47M | 171.00M | 171.00M | 170.00M | 167.00M | 164.00M | 156.30M | 151.30M | 146.07M |
| Weighted Average Shares Outstanding Diluted | 182.00M | 183.00M | 182.00M | 182.00M | 181.00M | 181.00M | 181.00M | 181.00M | 181.00M | 181.00M | 181.00M | 178.85M | 172.00M | 172.00M | 172.00M | 169.00M | 166.00M | 158.60M | 153.10M | 147.69M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | June 30, 2024 | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $289.00M | $280.00M | $449.00M | $896.00M | $953.20M |
| Short Term Investments | $109.00M | $- | $89.00M | $71.00M | $- |
| Cash and Short Term Investments | $289.00M | $280.00M | $538.00M | $967.00M | $953.20M |
| Net Receivables | $1.57B | $1.44B | $1.50B | $1.24B | $918.50M |
| Inventory | $574.00M | $764.00M | $702.00M | $563.00M | $323.80M |
| Other Current Assets | $168.00M | $196.00M | $180.00M | $145.00M | $97.50M |
| Total Current Assets | $2.60B | $2.68B | $2.92B | $2.92B | $2.29B |
| Property Plant Equipment Net | $3.72B | $3.70B | $3.13B | $2.52B | $1.90B |
| Goodwill | $2.33B | $3.04B | $3.01B | $2.52B | $2.47B |
| Intangible Assets | $841.00M | $980.00M | $1.06B | $817.00M | $888.70M |
| Goodwill and Intangible Assets | $3.17B | $4.02B | $4.07B | $3.34B | $3.36B |
| Long Term Investments | $47.00M | $-4.07B | $33.00M | $38.00M | $-3.41B |
| Tax Assets | $7.00M | $55.00M | $49.00M | $66.00M | $49.40M |
| Other Non-Current Assets | $208.00M | $4.40B | $316.00M | $230.00M | $3.58B |
| Total Non-Current Assets | $7.16B | $8.10B | $7.59B | $6.19B | $5.48B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $9.75B | $10.78B | $10.51B | $9.11B | $7.78B |
| Account Payables | $361.00M | $424.00M | $421.00M | $385.00M | $321.00M |
| Short Term Debt | $61.00M | $547.00M | $45.00M | $91.00M | $87.90M |
| Tax Payables | $16.00M | $44.00M | $50.00M | $30.00M | $4.50M |
| Deferred Revenue | $250.00M | $167.00M | $185.00M | $305.00M | $191.00M |
| Other Current Liabilities | $343.00M | $348.00M | $371.00M | $385.00M | $288.80M |
| Total Current Liabilities | $1.03B | $1.51B | $1.07B | $1.20B | $893.20M |
| Long Term Debt | $4.86B | $4.31B | $4.17B | $3.17B | $2.82B |
| Deferred Revenue Non-Current | $- | $-76.00M | $202.00M | $195.00M | $512.60M |
| Deferred Tax Liabilities Non-Current | $5.00M | $76.00M | $202.00M | $164.00M | $94.00M |
| Other Non-Current Liabilities | $256.00M | $247.00M | $464.00M | $312.00M | $1.07B |
| Total Non-Current Liabilities | $5.12B | $4.64B | $4.64B | $4.00B | $3.98B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $6.15B | $6.15B | $5.71B | $5.20B | $4.88B |
| Preferred Stock | $- | $24.00M | $10.51B | $359.00M | $606.60M |
| Common Stock | $2.00M | $2.00M | $2.00M | $2.00M | $1.60M |
| Retained Earnings | $-781.00M | $262.00M | $538.00M | $25.00M | $-535.20M |
| Accumulated Other Comprehensive Income Loss | $-404.00M | $-354.00M | $-394.00M | $-317.00M | $-386.30M |
| Other Total Stockholders Equity | $4.79B | $4.70B | $4.65B | $4.21B | $2.60B |
| Total Stockholders Equity | $3.60B | $4.63B | $4.79B | $3.92B | $2.90B |
| Total Equity | $3.60B | $4.63B | $4.79B | $3.92B | $2.90B |
| Total Liabilities and Stockholders Equity | $9.75B | $10.78B | $10.51B | $9.11B | $7.78B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $9.75B | $10.78B | $10.51B | $9.11B | $7.78B |
| Total Investments | $156.00M | $-4.07B | $122.00M | $109.00M | $-3.41B |
| Total Debt | $4.92B | $4.85B | $4.20B | $3.24B | $3.02B |
| Net Debt | $4.63B | $4.57B | $3.75B | $2.35B | $2.06B |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $335.00M | $289.00M | $162.00M | $229.00M | $209.00M | $280.00M | $252.00M | $442.00M | $281.00M | $449.00M | $786.00M | $849.00M | $1.97B | $896.00M | $988.10M | $833.10M | $1.01B | $953.20M | $608.40M | $188.90M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $28.00M | $64.00M | $89.00M | $94.00M | $66.00M | $50.00M | $71.00M | $74.70M | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $335.00M | $289.00M | $162.00M | $229.00M | $209.00M | $280.00M | $252.00M | $470.00M | $345.00M | $538.00M | $880.00M | $915.00M | $2.02B | $967.00M | $1.06B | $833.10M | $1.01B | $953.20M | $608.40M | $188.90M |
| Net Receivables | $1.46B | $1.57B | $1.41B | $1.37B | $1.40B | $1.44B | $1.57B | $1.45B | $1.44B | $1.50B | $1.30B | $1.21B | $1.12B | $1.24B | $1.05B | $927.80M | $840.60M | $918.50M | $746.30M | $716.50M |
| Inventory | $553.00M | $574.00M | $770.00M | $775.00M | $811.00M | $764.00M | $744.00M | $841.00M | $753.00M | $724.00M | $697.00M | $709.00M | $653.00M | $563.00M | $555.10M | $486.20M | $406.70M | $323.80M | $320.30M | $258.30M |
| Other Current Assets | $161.00M | $168.00M | $185.00M | $200.00M | $212.00M | $196.00M | $170.00M | $157.00M | $159.00M | $158.00M | $151.00M | $136.00M | $140.00M | $145.00M | $104.30M | $271.80M | $101.80M | $97.50M | $71.10M | $136.80M |
| Total Current Assets | $2.51B | $2.60B | $2.52B | $2.57B | $2.64B | $2.68B | $2.74B | $2.92B | $2.70B | $2.92B | $3.02B | $2.97B | $3.93B | $2.92B | $2.77B | $2.52B | $2.36B | $2.29B | $1.75B | $1.30B |
| Property Plant Equipment Net | $3.67B | $3.72B | $3.73B | $3.78B | $3.73B | $3.70B | $3.67B | $3.58B | $3.17B | $3.22B | $2.82B | $2.73B | $2.58B | $2.52B | $2.36B | $2.13B | $2.04B | $1.90B | $1.77B | $1.62B |
| Goodwill | $2.37B | $2.33B | $2.34B | $2.35B | $2.32B | $3.04B | $3.02B | $3.21B | $2.93B | $3.01B | $3.01B | $3.03B | $2.53B | $2.52B | $2.52B | $2.46B | $2.49B | $2.47B | $2.45B | $2.21B |
| Intangible Assets | $811.00M | $841.00M | $875.00M | $911.00M | $3.68B | $980.00M | $1.01B | $1.04B | $1.02B | $1.06B | $1.10B | $1.13B | $793.00M | $817.00M | $834.80M | $855.30M | $870.30M | $888.70M | $907.30M | $885.90M |
| Goodwill and Intangible Assets | $3.18B | $3.17B | $3.21B | $3.26B | $3.68B | $4.02B | $4.04B | $4.26B | $3.95B | $4.07B | $4.11B | $4.16B | $3.32B | $3.34B | $3.35B | $3.32B | $3.36B | $3.36B | $3.36B | $3.09B |
| Long Term Investments | $- | $156.00M | $85.00M | $76.00M | $-3.78B | $36.00M | $51.00M | $54.00M | $54.00M | $33.00M | $30.00M | $7.00M | $3.00M | $38.00M | $53.70M | $- | $- | $-3.41B | $- | $- |
| Tax Assets | $32.00M | $7.00M | $66.00M | $55.00M | $100.00M | $55.00M | $42.00M | $55.00M | $45.00M | $49.00M | $68.00M | $65.00M | $70.00M | $66.00M | $44.10M | $44.60M | $57.10M | $49.40M | $45.10M | $35.10M |
| Other Non-Current Assets | $321.00M | $99.00M | $256.00M | $248.00M | $3.68B | $294.00M | $293.00M | $281.00M | $295.00M | $223.00M | $270.00M | $272.00M | $274.00M | $230.00M | $188.20M | $188.00M | $174.80M | $3.58B | $162.30M | $147.90M |
| Total Non-Current Assets | $7.20B | $7.16B | $7.36B | $7.42B | $7.41B | $8.10B | $8.09B | $8.23B | $7.51B | $7.59B | $7.30B | $7.23B | $6.25B | $6.19B | $5.99B | $5.68B | $5.63B | $5.48B | $5.33B | $4.89B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $9.71B | $9.75B | $9.88B | $9.99B | $10.05B | $10.78B | $10.83B | $11.15B | $10.21B | $10.51B | $10.32B | $10.20B | $10.18B | $9.11B | $8.77B | $8.20B | $7.98B | $7.78B | $7.08B | $6.20B |
| Account Payables | $375.00M | $361.00M | $377.00M | $407.00M | $367.00M | $424.00M | $394.00M | $367.00M | $379.00M | $421.00M | $401.00M | $363.00M | $363.00M | $385.00M | $365.70M | $356.90M | $329.40M | $321.00M | $276.20M | $243.40M |
| Short Term Debt | $61.00M | $61.00M | $57.00M | $55.00M | $635.00M | $547.00M | $599.00M | $644.00M | $119.00M | $45.00M | $43.00M | $43.00M | $93.00M | $91.00M | $88.10M | $72.00M | $73.40M | $87.90M | $271.80M | $72.40M |
| Tax Payables | $6.00M | $16.00M | $14.00M | $28.00M | $44.00M | $44.00M | $23.00M | $34.00M | $42.00M | $50.00M | $36.00M | $20.00M | $25.00M | $30.00M | $59.90M | $200.00K | $- | $4.50M | $- | $5.40M |
| Deferred Revenue | $272.00M | $250.00M | $249.00M | $214.00M | $179.00M | $167.00M | $203.00M | $175.00M | $135.00M | $211.00M | $190.00M | $271.00M | $283.00M | $305.00M | $289.00M | $260.60M | $229.40M | $191.00M | $160.20M | $165.60M |
| Other Current Liabilities | $284.00M | $343.00M | $310.00M | $332.00M | $309.00M | $348.00M | $268.00M | $306.00M | $268.00M | $371.00M | $376.00M | $348.00M | $332.00M | $385.00M | $336.50M | $334.30M | $287.50M | $288.80M | $208.90M | $171.30M |
| Total Current Liabilities | $998.00M | $1.03B | $1.01B | $1.04B | $1.54B | $1.51B | $1.49B | $1.53B | $943.00M | $1.10B | $1.05B | $1.04B | $1.10B | $1.20B | $1.14B | $1.02B | $919.70M | $893.20M | $917.10M | $658.10M |
| Long Term Debt | $4.89B | $4.93B | $4.93B | $4.96B | $4.32B | $4.75B | $4.26B | $4.22B | $4.10B | $4.17B | $4.16B | $4.19B | $4.22B | $3.17B | $3.15B | $2.98B | $2.99B | $2.82B | $2.93B | $2.82B |
| Deferred Revenue Non-Current | $- | $382.00M | $97.00M | $5.00M | $-68.00M | $-76.00M | $- | $221.00M | $214.00M | $103.00M | $8.00M | $127.00M | $133.00M | $195.00M | $140.00M | $141.90M | $135.50M | $512.60M | $137.60M | $138.40M |
| Deferred Tax Liabilities Non-Current | $- | $5.00M | $64.00M | $50.00M | $68.00M | $76.00M | $119.00M | $221.00M | $214.00M | $197.00M | $211.00M | $189.00M | $171.00M | $164.00M | $100.30M | $66.50M | $83.60M | $94.00M | $95.60M | $76.10M |
| Other Non-Current Liabilities | $282.00M | $-196.00M | $264.00M | $256.00M | $258.00M | $-186.00M | $260.00M | $267.00M | $250.00M | $464.00M | $276.00M | $297.00M | $311.00M | $312.00M | $307.80M | $309.30M | $316.90M | $1.07B | $345.70M | $313.80M |
| Total Non-Current Liabilities | $5.17B | $5.12B | $5.26B | $5.26B | $4.60B | $4.64B | $4.64B | $4.71B | $4.56B | $4.63B | $4.64B | $4.68B | $4.71B | $4.00B | $3.56B | $3.36B | $3.39B | $3.98B | $3.37B | $3.21B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $6.17B | $6.15B | $6.27B | $6.30B | $6.14B | $6.15B | $6.13B | $6.24B | $5.50B | $5.73B | $5.69B | $5.72B | $5.80B | $5.20B | $4.70B | $4.38B | $4.31B | $4.88B | $4.29B | $3.87B |
| Preferred Stock | $- | $- | $- | $1.05B | $883.00M | $- | $- | $- | $- | $10.51B | $10.32B | $10.20B | $359.00M | $359.00M | $359.00M | $359.00M | $606.60M | $606.60M | $606.60M | $606.60M |
| Common Stock | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $1.70M | $1.70M | $1.60M | $1.60M | $1.50M | $1.50M |
| Retained Earnings | $-910.00M | $-781.00M | $-804.00M | $-703.00M | $-497.00M | $262.00M | $372.00M | $619.00M | $538.00M | $518.00M | $350.00M | $209.00M | $114.00M | $25.00M | $-150.30M | $-377.40M | $-460.90M | $-535.20M | $-681.20M | $-694.00M |
| Accumulated Other Comprehensive Income Loss | $-350.00M | $-404.00M | $-356.00M | $-354.00M | $-388.00M | $-354.00M | $-368.00M | $-395.00M | $-514.00M | $-394.00M | $-350.00M | $-345.00M | $-329.00M | $-317.00M | $-323.90M | $-329.60M | $-370.00M | $-386.30M | $-393.60M | $-350.60M |
| Other Total Stockholders Equity | $4.80B | $4.79B | $4.77B | $4.74B | $4.72B | $4.70B | $4.70B | $4.69B | $4.67B | $4.65B | $4.63B | $4.62B | $4.23B | $4.21B | $4.19B | $4.16B | $3.90B | $2.60B | $3.26B | $2.76B |
| Total Stockholders Equity | $3.54B | $3.60B | $3.61B | $3.69B | $3.90B | $4.63B | $4.70B | $4.91B | $4.70B | $4.78B | $4.63B | $4.48B | $4.38B | $3.92B | $4.07B | $3.81B | $3.68B | $2.90B | $2.79B | $2.32B |
| Total Equity | $3.54B | $3.60B | $3.61B | $3.69B | $3.90B | $4.63B | $4.70B | $4.91B | $4.70B | $4.78B | $4.63B | $4.48B | $4.38B | $3.92B | $4.07B | $3.81B | $3.68B | $2.90B | $2.79B | $2.32B |
| Total Liabilities and Stockholders Equity | $9.71B | $9.75B | $9.88B | $9.99B | $10.05B | $10.78B | $10.83B | $11.15B | $10.21B | $10.51B | $10.32B | $10.20B | $10.18B | $9.11B | $8.77B | $8.20B | $7.98B | $7.78B | $7.08B | $6.20B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $9.71B | $9.75B | $9.88B | $9.99B | $10.05B | $10.78B | $10.83B | $11.15B | $10.21B | $10.51B | $10.32B | $10.20B | $10.18B | $9.11B | $8.77B | $8.20B | $7.98B | $7.78B | $7.08B | $6.20B |
| Total Investments | $23.00M | $156.00M | $85.00M | $76.00M | $-3.78B | $36.00M | $51.00M | $28.00M | $64.00M | $158.00M | $94.00M | $66.00M | $50.00M | $109.00M | $74.70M | $- | $- | $-3.41B | $- | $- |
| Total Debt | $4.95B | $4.99B | $4.99B | $5.01B | $4.95B | $4.85B | $4.85B | $4.87B | $4.22B | $4.22B | $4.20B | $4.23B | $4.32B | $3.24B | $3.24B | $3.06B | $3.06B | $3.02B | $3.20B | $2.90B |
| Net Debt | $4.61B | $4.70B | $4.83B | $4.79B | $4.74B | $4.57B | $4.60B | $4.42B | $3.94B | $3.77B | $3.41B | $3.38B | $2.35B | $2.35B | $2.25B | $2.22B | $2.05B | $2.06B | $2.59B | $2.71B |
Annual Cash Flow
| Breakdown | June 30, 2024 | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 |
|---|---|---|---|---|---|
| Net Income | $-1.04B | $-256.00M | $519.00M | $585.00M | $220.70M |
| Depreciation and Amortization | $489.00M | $422.00M | $378.00M | $289.00M | $253.70M |
| Deferred Income Tax | $-28.00M | $-127.00M | $14.00M | $64.00M | $2.40M |
| Stock Based Compensation | $68.00M | $35.00M | $54.00M | $51.00M | $48.00M |
| Change in Working Capital | $-62.00M | $-160.00M | $-612.00M | $-432.00M | $-121.30M |
| Accounts Receivables | $79.00M | $53.00M | $-73.00M | $-186.00M | $-150.90M |
| Inventory | $109.00M | $-192.00M | $-128.00M | $-260.00M | $-76.40M |
| Accounts Payables | $-84.00M | $-21.00M | $37.00M | $50.00M | $72.20M |
| Other Working Capital | $-166.00M | $160.00M | $-448.00M | $-36.00M | $33.80M |
| Other Non Cash Items | $844.00M | $347.00M | $86.00M | $-124.00M | $36.70M |
| Net Cash Provided by Operating Activities | $268.00M | $261.00M | $439.00M | $433.00M | $440.30M |
| Investments in Property Plant and Equipment | $-327.00M | $-583.00M | $-660.00M | $-686.00M | $-465.80M |
| Acquisitions Net | $- | $-474.00M | $-1.20B | $140.00M | $-358.90M |
| Purchases of Investments | $-1.00M | $-2.00M | $-22.00M | $-103.00M | $-2.80M |
| Sales Maturities of Investments | $- | $89.00M | $665.00M | $430.00M | $447.80M |
| Other Investing Activities | $1.00M | $8.00M | $-665.00M | $-430.00M | $-447.80M |
| Net Cash Used for Investing Activities | $-327.00M | $-962.00M | $-1.88B | $-649.00M | $-827.50M |
| Debt Repayment | $84.00M | $485.00M | $1.02B | $99.00M | $23.20M |
| Common Stock Issued | $9.00M | $4.00M | $362.00M | $82.00M | $1.05B |
| Common Stock Repurchased | $- | $- | $-10.00M | $- | $- |
| Dividends Paid | $- | $- | $-4.00M | $-22.00M | $-36.20M |
| Other Financing Activities | $-19.00M | $36.00M | $13.00M | $-17.00M | $-31.30M |
| Net Cash Used Provided by Financing Activities | $74.00M | $521.00M | $1.03B | $142.00M | $1.00B |
| Effect of Forex Changes on Cash | $-6.00M | $11.00M | $-33.00M | $17.00M | $-6.70M |
| Net Change in Cash | $9.00M | $-169.00M | $-447.00M | $-57.00M | $607.80M |
| Cash at End of Period | $289.00M | $280.00M | $449.00M | $896.00M | $953.20M |
| Cash at Beginning of Period | $280.00M | $449.00M | $896.00M | $953.00M | $345.40M |
| Operating Cash Flow | $268.00M | $261.00M | $439.00M | $433.00M | $440.30M |
| Capital Expenditure | $-327.00M | $-583.00M | $-660.00M | $-686.00M | $-465.80M |
| Free Cash Flow | $-59.00M | $-322.00M | $-221.00M | $-253.00M | $-25.50M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-129.00M | $23.00M | $-101.00M | $-206.00M | $-759.00M | $-110.00M | $-227.00M | $81.00M | $-2.00M | $188.00M | $141.00M | $97.00M | $93.00M | $182.40M | $231.80M | $88.40M | $82.40M | $154.20M | $20.90M | $45.50M |
| Depreciation and Amortization | $113.00M | $130.00M | $126.00M | $121.00M | $112.00M | $114.00M | $106.00M | $103.00M | $99.00M | $100.00M | $99.00M | $98.00M | $81.00M | $73.00M | $75.90M | $71.00M | $69.10M | $66.40M | $64.80M | $61.90M |
| Deferred Income Tax | $-5.00M | $-4.00M | $3.00M | $17.00M | $-44.00M | $-58.00M | $-82.00M | $17.00M | $-4.00M | $1.00M | $12.00M | $9.00M | $-8.00M | $46.20M | $23.10M | $5.30M | $-10.60M | $-3.00M | $2.70M | $3.30M |
| Stock Based Compensation | $17.00M | $16.00M | $17.00M | $16.00M | $19.00M | $- | $6.00M | $10.00M | $19.00M | $12.00M | $10.00M | $11.00M | $21.00M | $12.50M | $8.40M | $11.40M | $18.70M | $12.60M | $8.60M | $10.30M |
| Change in Working Capital | $46.00M | $45.00M | $-101.00M | $101.00M | $56.00M | $113.00M | $-120.00M | $-20.00M | $-261.00M | $-252.00M | $-132.00M | $-179.00M | $-49.00M | $-188.60M | $-135.30M | $-99.60M | $-8.50M | $-32.60M | $-18.80M | $-4.20M |
| Accounts Receivables | $173.00M | $-51.00M | $-35.00M | $5.00M | $160.00M | $35.00M | $-130.00M | $117.00M | $31.00M | $-133.00M | $-71.00M | $-54.00M | $185.00M | $-184.80M | $-88.80M | $-56.10M | $143.70M | $-135.40M | $-19.80M | $-29.80M |
| Inventory | $-10.00M | $170.00M | $-15.00M | $-15.00M | $-31.00M | $-57.00M | $45.00M | $-95.00M | $-85.00M | $-35.00M | $55.00M | $-85.00M | $-63.00M | $-20.00M | $-99.70M | $-74.90M | $-65.40M | $-21.70M | $-43.10M | $-11.80M |
| Accounts Payables | $-10.00M | $-26.00M | $-18.00M | $33.00M | $-73.00M | $18.00M | $29.00M | $-16.00M | $-52.00M | $71.00M | $-37.00M | $9.00M | $-6.00M | $13.40M | $23.20M | $6.80M | $6.60M | $42.30M | $43.20M | $34.00M |
| Other Working Capital | $-107.00M | $-48.00M | $-33.00M | $78.00M | $-56.00M | $117.00M | $-64.00M | $-26.00M | $-155.00M | $-155.00M | $-79.00M | $-49.00M | $-165.00M | $2.80M | $30.00M | $24.60M | $-93.40M | $82.20M | $900.00K | $3.40M |
| Other Non Cash Items | $19.00M | $187.00M | $4.00M | $63.00M | $546.00M | $2.00M | $253.00M | $23.00M | $57.00M | $2.00M | $8.00M | $33.00M | $25.00M | $8.80M | $-128.90M | $-2.50M | $-1.40M | $-24.90M | $43.50M | $3.90M |
| Net Cash Provided by Operating Activities | $61.00M | $214.00M | $12.00M | $112.00M | $-70.00M | $203.00M | $-64.00M | $214.00M | $-92.00M | $69.00M | $138.00M | $69.00M | $163.00M | $134.30M | $75.00M | $74.00M | $149.70M | $172.70M | $121.70M | $120.70M |
| Investments in Property Plant and Equipment | $-57.00M | $-75.00M | $-74.00M | $-94.00M | $-84.00M | $-128.00M | $-138.00M | $-168.00M | $-149.00M | $-235.00M | $-148.00M | $-123.00M | $-154.00M | $-188.90M | $-158.20M | $-189.30M | $-149.60M | $-162.30M | $-151.30M | $-78.70M |
| Acquisitions Net | $23.00M | $-1.00M | $- | $- | $1.00M | $- | $1.00M | $-474.00M | $6.00M | $-166.00M | $-13.00M | $-994.00M | $-29.00M | $300.00K | $154.50M | $-14.80M | $- | $-20.80M | $-313.90M | $-34.30M |
| Purchases of Investments | $- | $1.00M | $- | $-1.00M | $-1.00M | $- | $-1.00M | $-1.00M | $-6.00M | $7.00M | $-26.00M | $1.00M | $-4.00M | $-24.00M | $-78.00M | $600.00K | $-1.60M | $-400.00K | $-400.00K | $-1.30M |
| Sales Maturities of Investments | $- | $1.00M | $- | $- | $-1.00M | $- | $28.00M | $34.00M | $27.00M | $-4.00M | $-4.00M | $-16.00M | $20.00M | $- | $- | $- | $- | $468.60M | $- | $- |
| Other Investing Activities | $- | $-352.00M | $- | $-1.00M | $1.00M | $- | $28.00M | $1.00M | $6.00M | $7.00M | $-4.00M | $-15.00M | $13.00M | $-500.00K | $200.00K | $300.00K | $-1.00M | $-447.80M | $-400.00K | $19.50M |
| Net Cash Used for Investing Activities | $-34.00M | $-74.00M | $-74.00M | $-95.00M | $-84.00M | $-128.00M | $-110.00M | $-608.00M | $-116.00M | $-394.00M | $-191.00M | $-1.13B | $-167.00M | $-213.10M | $-81.50M | $-203.20M | $-151.20M | $-162.70M | $-465.60M | $-114.30M |
| Debt Repayment | $-5.00M | $-5.00M | $245.00M | $-2.00M | $115.00M | $-58.00M | $-54.00M | $550.00M | $68.00M | $- | $-8.00M | $-42.00M | $1.10B | $-14.70M | $148.00M | $-47.00M | $-6.30M | $-206.70M | $1.07B | $-51.60M |
| Common Stock Issued | $1.00M | $-9.00M | $- | $- | $- | $- | $3.00M | $- | $1.00M | $5.00M | $2.00M | $11.00M | $8.00M | $200.00K | $- | $- | $83.60M | $552.30M | $494.20M | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.00M | $- | $-5.00M | $-4.00M | $- | $- | $- | $- | $- | $- | $-6.30M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-4.00M | $-4.30M | $-4.70M | $-4.90M | $-8.10M | $-8.10M | $-8.10M | $-8.10M |
| Other Financing Activities | $-6.00M | $-5.00M | $-245.00M | $-12.00M | $-18.00M | $7.00M | $29.00M | $-27.00M | $6.00M | $1.00M | $5.00M | $-7.00M | $-10.00M | $1.50M | $1.10M | $-3.00M | $-18.00M | $-6.50M | $-783.40M | $-6.30M |
| Net Cash Used Provided by Financing Activities | $-10.00M | $-10.00M | $- | $-14.00M | $98.00M | $-51.00M | $-25.00M | $523.00M | $74.00M | $1.00M | $-3.00M | $-49.00M | $1.08B | $-17.30M | $166.50M | $-56.80M | $49.60M | $331.00M | $772.50M | $-66.00M |
| Effect of Forex Changes on Cash | $29.00M | $-3.00M | $-5.00M | $17.00M | $-15.00M | $4.00M | $9.00M | $32.00M | $-34.00M | $-13.00M | $-7.00M | $-8.00M | $-5.00M | $4.20M | $-5.00M | $12.10M | $5.70M | $3.80M | $-9.10M | $5.10M |
| Net Change in Cash | $46.00M | $127.00M | $-67.00M | $20.00M | $-71.00M | $28.00M | $-190.00M | $161.00M | $-168.00M | $-337.00M | $-63.00M | $-1.12B | $1.07B | $-92.10M | $155.00M | $-173.90M | $53.80M | $344.80M | $419.50M | $-54.50M |
| Cash at End of Period | $335.00M | $289.00M | $162.00M | $229.00M | $209.00M | $280.00M | $252.00M | $442.00M | $281.00M | $449.00M | $786.00M | $849.00M | $1.97B | $896.00M | $988.10M | $833.10M | $1.01B | $953.20M | $608.40M | $188.90M |
| Cash at Beginning of Period | $289.00M | $162.00M | $229.00M | $209.00M | $280.00M | $252.00M | $442.00M | $281.00M | $449.00M | $786.00M | $849.00M | $1.97B | $896.00M | $988.10M | $833.10M | $1.01B | $953.20M | $608.40M | $188.90M | $243.40M |
| Operating Cash Flow | $61.00M | $214.00M | $12.00M | $112.00M | $-70.00M | $203.00M | $-64.00M | $214.00M | $-92.00M | $69.00M | $138.00M | $69.00M | $163.00M | $134.30M | $75.00M | $74.00M | $149.70M | $172.70M | $121.70M | $120.70M |
| Capital Expenditure | $-57.00M | $-75.00M | $-74.00M | $-94.00M | $-84.00M | $-128.00M | $-138.00M | $-168.00M | $-149.00M | $-235.00M | $-148.00M | $-123.00M | $-154.00M | $-188.90M | $-158.20M | $-189.30M | $-149.60M | $-162.30M | $-151.30M | $-78.70M |
| Free Cash Flow | $4.00M | $139.00M | $-62.00M | $18.00M | $-154.00M | $75.00M | $-202.00M | $46.00M | $-241.00M | $-166.00M | $-10.00M | $-54.00M | $9.00M | $-54.60M | $-83.20M | $-115.30M | $100.00K | $10.40M | $-29.60M | $42.00M |
Catalent Dividends
Explore Catalent's dividend history, including dividend yield, payout ratio, and historical payments.
Catalent News
Read the latest news about Catalent, including recent articles, headlines, and updates.
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.
Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400
NEW YORK , Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE: LII) will replace Catalent Inc. (NYSE: CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE: BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December 18.
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.
Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction
SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now expect to close the transaction in the coming days. “Today represents an important step in our t.
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk's subsequent acquisition of three manufacturing sites from Novo Holdings A/S.
Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction
SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the European Commission (EC) has granted unconditional approval for the pending transaction under which Novo Holdings will acquire Catalent. “We are pleased to have received European Commission approval, whic.
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk.
Consumer groups ask FTC to block Novo Holdings-Catalent deal
Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's controlling shareholder from acquiring contract drug manufacturer Catalent , saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.
Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent
Ghent, Belgium, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, today announced it has signed a definitive agreement to acquire Catalent's state-of-the-art facility in Somerset, New Jersey. This acquisition will significantly enhance Ardena's capabilities in downstream late-stage and small-scale commercial manufacturing of oral drug products, supporting its strategy to become a leading global CDMO offering integrated solutions across the entire pharmaceutical development lifecycle.
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden. Financial details of the agreement, which is expected.
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent , saying it may give the pharmaceutical company an unlawful advantage in weight loss and obesity drugs.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CTLT.